Polysiloxane Gd-Chelates based nanoparticles (AGuIX)

DRUG2 trials

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris, Centre Jean Perrin

Conditions

GlioblastomaGynecologic Cancer

Phase 1

AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy

Gustave Roussy, Cancer Campus, Grand ParisGynecologic Cancer

Start: 2018-05-17End: 2024-05-31Target: 18Updated: 2021-07-07

AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma

Active, not recruitingNCT04881032

Centre Jean PerrinGlioblastoma

Start: 2022-03-07End: 2027-03-31Updated: 2025-02-13

Related Papers

NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution.

2024-07-319 citations

Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)

BMC Cancer2023-04-1549 citations